Kala Pharmaceuticals Announces $22.5 Million Series B Financing

por Ysios Capital

Kala Pharmaceuticals, Inc., a leading developer of innovative ophthalmic products based on the company’s proprietary Mucus Penetrating Particle (MPP) platform technology, today announced it has comp...

Leer más
Subscribirse al Directorio
Escribir un Artículo

Destacadas

3i closes second European CLO, Harvest V...

by 3i Group

senior secured loans backing private equity buyouts

ViaGalicia, Lanzadera y Orizont lideran ...

by Professional Newco

El informe registra un centenar de aceleradoras en España, con una cl...

Diapositiva de Fotos